HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of acute puerperal metritis with flunixin meglumine in addition to antibiotic treatment.

Abstract
The objective of this field trial was to evaluate effects of a single administration of 2.2 mg/kg of body weight (BW) of flunixin meglumine (FM) in addition to a systemic antibiotic treatment in cows with acute puerperal metritis (APM). Outcome variables tested were proportion of cows with a fever, prevalence of chronic endometritis 18 to 22 and 32 to 35 d in milk (DIM), and reproductive performance measures in the current lactation. In addition, serum concentrations of haptoglobin and fibrinogen were analyzed. Daily milk yield within 6 d after the first treatment was recorded. Cows were examined 4 to 5 DIM by rectal palpation and vaginoscopy, and rectal temperature was measured. Fetid vulvar discharge and a body temperature > or = 39.5 degrees C were signs of APM. Cows with APM were treated in the reference group with 1.0 mg/kg of BW of ceftiofur on 3 to 5 consecutive days (CEF, n = 119). In the study group, cows received the same antibiotic treatment as in CEF and 2.2 mg/kg of BW of FM on treatment d 1 (CEF + FM, n = 119). Blood samples were collected 4, 6, and 10 DIM and analyzed for concentrations of haptoglobin and fibrinogen. A group of cows without APM remained untreated and served as controls (n = 9). There were no significant differences between CEF and CEF + FM in the proportion of cows with fever 1 d after the first treatment (33.6 vs. 46.2%), milk yield per milking 10 DIM (7.5 +/- 0.3 vs. 7.6 +/- 0.3 kg in primiparous, 9.6 +/- 0.4 vs. 10.6 +/- 0.4 kg in multiparous cows), prevalence of chronic endometritis 32 to 35 DIM (64.3 vs. 52.2%), and in reproductive performance (31.5 vs. 34.3% conception to first AI, 58.0 vs. 54.6% pregnancy rate, 107.8 +/- 36.9 vs. 101.6 +/- 41.4 d open). Compared with the control, CEF and CEF + FM had significantly greater concentrations of haptoglobin (1.1 +/- 0.28 vs. 1.9 +/- 0.06 and 1.8 +/- 0.07 mg/mL at 4 DIM; 0.3 +/- 0.15 vs. 1.1 +/- 0.06 and 1.2 +/- 0.07 mg/mL at 10 DIM) and fibrinogen (2.2 +/- 0.17 vs. 3.9 +/- 0.14 and 3.7 +/- 0.13 g/L at 4 DIM; 1.9 +/- 0.1 vs. 2.6 +/- 0.1 and 3.0 +/- 0.13 g/L, respectively, at 10 DIM) on all test days. The additional treatment with FM had no effect on these acute phase proteins. In conclusion, the single administration of 2.2 mg/kg of BW of FM in addition to a systemic antibiotic treatment of cows having APM did not result in beneficial effects on clinical cure, milk yield within 6 d after the first treatment, or reproductive performance.
AuthorsM Drillich, D Voigt, D Forderung, W Heuwieser
JournalJournal of dairy science (J Dairy Sci) Vol. 90 Issue 8 Pg. 3758-63 (Aug 2007) ISSN: 1525-3198 [Electronic] United States
PMID17638987 (Publication Type: Clinical Trial, Comparative Study, Journal Article)
Chemical References
  • Anti-Bacterial Agents
  • Anti-Inflammatory Agents, Non-Steroidal
  • Cephalosporins
  • Haptoglobins
  • ceftiofur
  • flunixin meglumine
  • Fibrinogen
  • Clonixin
Topics
  • Animals
  • Anti-Bacterial Agents (administration & dosage, pharmacology)
  • Anti-Inflammatory Agents, Non-Steroidal (administration & dosage, pharmacology)
  • Blood Chemical Analysis
  • Cattle
  • Cattle Diseases (drug therapy, epidemiology)
  • Cephalosporins (administration & dosage, pharmacology)
  • Clonixin (administration & dosage, analogs & derivatives, pharmacology)
  • Dairying (methods)
  • Drug Therapy, Combination
  • Endometritis (drug therapy, epidemiology, veterinary)
  • Female
  • Fibrinogen (analysis)
  • Haptoglobins (analysis)
  • Lactation (drug effects)
  • Postpartum Period
  • Puerperal Disorders (drug therapy, veterinary)
  • Reproduction (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: